pfizer news - Search News

Pfizer, Haleon

Pfizer to sell $3 billion stake in Sensodyne maker Haleon

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan said on Wednesday.

Wall Street Journal · 9h

Pfizer Sells 700 Million Haleon Shares for $3.05 Billion

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.

invezz on MSN · 5h

Why Pfizer sold its $3 billion stake in Haleon

Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each,

Reuters · 23h

Pfizer to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner

Pfizer is looking to sell about 700 million ordinary shares in Haleon , its bookrunner J.P. Morgan said on Tuesday, lowering its stake in the British consumer healthcare company to about 7.3% from 15%.

Seeking Alpha on MSN · 23h

Pfizer to cut Haleon stake in 700M share sale

Pfizer (NYSE:PFE) announced Tuesday it plans to sell roughly 700M ordinary shares in Haleon (NYSE:HLN) to lower its stake in the British consumer healthcare giant from about 15.0% to 7.3%, implying a divestment of approximately 7.

18h

Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund

Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...

20h

Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

STAT1d

Defiant, Pfizer CEO talks about Trump, obesity drugs, and the ‘Pfizer machine’

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy

Vaxcyte's robust financial position supports its strategic flexibility and extended timelines. Read more to see why I rate ...

1don MSN

Pfizer CEO Albert Bourla: Our 2025 focus is on pipeline

Albert Bourla, Pfizer chairman and CEO, joins CNBC's 'Power Lunch' to discuss the company's focus for 2025, whether bird flu ...

BioSpace2h

Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

FiercePharma1d

JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Pfizer’s Growth Potential and Strategic Focus Justify Buy Rating Amid Healthcare Policy Shifts

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

BioSpace1d

Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Hosted on MSN16h

Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Pfizer (PFE) closed at $26.41, marking a -1.46% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.12%. At the same time, the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Pfizer, Haleon

Related topics